Rallybio Corporation
RLYB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $42 | $54 | $41 | $27 |
| G&A Expenses | $20 | $25 | $27 | $19 |
| SG&A Expenses | $20 | $25 | $27 | $19 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $61 | $79 | $68 | $46 |
| Operating Income | -$60 | -$79 | -$68 | -$46 |
| % Margin | -9,511.9% | – | – | – |
| Other Income/Exp. Net | $3 | $4 | $0 | -$1 |
| Pre-Tax Income | -$58 | -$75 | -$68 | -$47 |
| Tax Expense | $0 | $0 | -$1 | $0 |
| Net Income | -$58 | -$75 | -$67 | -$47 |
| % Margin | -9,084.1% | – | – | – |
| EPS | -1.33 | -1.84 | -2.09 | -1.46 |
| % Growth | 27.7% | 12% | -43.2% | – |
| EPS Diluted | -1.33 | -1.84 | -2.09 | -1.46 |
| Weighted Avg Shares Out | 44 | 40 | 32 | 32 |
| Weighted Avg Shares Out Dil | 44 | 40 | 32 | 32 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $6 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$60 | -$79 | -$68 | -$45 |
| % Margin | -9,491.4% | – | – | – |